G01N 2800/50
Determining the risk of developing a disease
G01N2800/50 (Determining the risk of developing a disease) appears on 1,137 US grants and 2,884 published applications in this corpus.
Search patents in G01N- Granted patents
- 1,137
- Published applications
- 2,884
- Assignees
- 1,253
- Inventors
- 5,407
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 5 |
| 2004 | 0 | 4 |
| 2005 | 0 | 2 |
| 2006 | 1 | 5 |
| 2007 | 1 | 5 |
| 2008 | 3 | 29 |
| 2009 | 1 | 44 |
| 2010 | 6 | 75 |
| 2011 | 17 | 105 |
| 2012 | 18 | 133 |
| 2013 | 42 | 146 |
| 2014 | 52 | 163 |
| 2015 | 47 | 188 |
| 2016 | 73 | 242 |
| 2017 | 69 | 194 |
| 2018 | 99 | 231 |
| 2019 | 116 | 198 |
| 2020 | 107 | 171 |
| 2021 | 112 | 185 |
| 2022 | 87 | 157 |
| 2023 | 69 | 152 |
| 2024 | 86 | 161 |
| 2025 | 83 | 144 |
| 2026 | 40 | 143 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for the detection and treatment of ovarian cancer22 Sep 2026US 12,742,780 B2Board of Regents, The University of Texas System
- Methods for apolipoprotein detection15 Sep 2026US 12,736,545 B2Biocross, S.L.
- Detection of Alzheimer's disease using specific biomarkers25 Aug 2026US 12,716,901 B2St. Jude Children?S Research Hospital
- Molecular fingerprinting methods to detect and genotype DNA targets through polymerase chain reaction28 Jul 2026US 12,692,538 B2Ulisse Biomed S.P.A.
- Oxyntomodulin binding molecules, and uses thereof14 Jul 2026US 12,679,889 B2Eli Lilly and Company
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Electrochemical biosensors, systems, and methods of use8 Oct 2026US 2026/0309671 A1
- Method for evaluating onset risk of non-alcoholic fatty liver disease, and biomarkers8 Oct 2026US 2026/0309702 A1Shimadzu Corporation
- Oxyntomodulin binding molecules, and uses thereof1 Oct 2026US 2026/0297182 A1Eli Lilly and Company
- Patrolling monocyte cellular therapy1 Oct 2026US 2026/0297525 A1New York Blood Center, Inc.
Most cited
By later US patents
- Antagonist antibodies against GDF-872US 7,888,486 B2Wyeth · 2011
- Method for determining insulin sensitivity with biomarkers68US 8,187,830 B2Metabolon, Inc. · 2012
- Highly sensitive system and methods for analysis of troponin50US 7,838,250 B1Singulex, Inc. · 2010
- Predicting risk of major adverse cardiac events47US 8,090,562 B2Critical Care Diagnostics, Inc. · 2012
- Predicting mortality and detecting severe disease43US 7,998,683 B2Critical Care Diagnostics, Inc. · 2011